Biomedical scaffolds,designed for localizedtherapeutic delivery.
KINETIX is a biomedical scaffold development company building AI-guided, 3D-printed scaffold systems for localized and sustained therapeutic delivery, with glioblastoma as our first case study.
Investigational technology · Not approved for clinical use
A scaffold development platform for localized therapeutic delivery.
KINETIX is developing AI-guided, 3D-printed scaffold systems designed to deliver therapeutics directly at a target site, in a sustained and controlled manner. Our platform combines computational design with additive manufacturing to make scaffold geometry a meaningful variable in how drugs are delivered.
Platform Company
KINETIX is building a scaffold development platform, not a single-indication product. The design tools, fabrication methods, and computational approaches we develop are intended to work across therapeutic applications.
AI-Guided Design
We use computational methods to explore scaffold architecture in a more directed way than manual iteration alone allows. The goal is to make scaffold design systematic and reproducible.
3D-Printed Structures
Additive manufacturing enables precise, tunable porous geometries at implantable scales. Scaffold structure is treated as an active variable in delivery, not just a passive container.
GBM presents a formidable delivery challenge.
Glioblastoma multiforme remains one of the most challenging brain tumors to treat. Post-resection local delivery is an area where more targeted delivery strategies may offer meaningful benefit, and where KINETIX is focusing its initial development work.
The Blood-Brain Barrier
The BBB restricts the vast majority of systemically administered agents from reaching intracranial tumor tissue at meaningful concentrations, creating a fundamental pharmacological challenge in GBM treatment.
Local Recurrence After Resection
GBM tends to recur at or near the surgical cavity following resection. Post-surgical local delivery is an important area of ongoing investigation and represents a key focus for KINETIX.
Systemic Delivery Constraints
Whole-body drug administration exposes healthy tissue to therapeutic agents, limiting the doses that can be safely administered and constraining achievable tumor-site concentration.
Combining computation, architecture, and additive manufacturing to deliver therapy where it matters.
AI-Guided Design
Computational design tools are being developed to guide scaffold architecture toward specific therapeutic goals. The aim is to reduce dependence on manual trial-and-error by using AI to explore scaffold design space in a more directed way.
3D-Printed Scaffold Architecture
Additive manufacturing enables the fabrication of complex, tunable porous structures at implantable scale. Scaffold geometry is designed to be a variable in how therapeutics are delivered, not merely a passive container.
Localized Sustained Delivery
Scaffolds are being developed for post-resection implantation, designed to maintain local drug concentrations over time. The intent is to deliver therapy directly at the target site while reducing systemic exposure.
First case study:
glioblastoma.
Glioblastoma multiforme (GBM) is a high-grade primary brain tumor with a challenging prognosis. It represents the first application KINETIX is pursuing, chosen because the post-resection local delivery context is well-suited to scaffold-based approaches.
Post-Resection Context
GBM surgery removes visible tumor mass, but microscopic residual disease near the resection cavity remains a persistent challenge. KINETIX is developing scaffold systems being designed for post-resection local delivery applications in this context.
Local Delivery Approach
By placing a scaffold directly at the surgical site, the aim is to establish sustained local drug presence over time. This approach aims to address delivery limitations associated with systemic administration in intracranial disease.
Investigational Development
KINETIX's GBM program is at an early research and development stage. Current work focuses on scaffold design, material selection, and building toward preclinical evaluation. The technology is not yet in clinical use.
Geometry as a delivery variable.
Scaffold architecture can be a meaningful variable in how therapeutics are delivered, not just the chemistry, but the physical structure itself.
Structure, Not Chemistry Alone
Traditional drug delivery relies primarily on chemical formulation to modulate release. KINETIX's approach is designed around the idea that scaffold architecture can serve as an additional control variable, influencing how and when therapeutics interact with surrounding tissue.
Scaffold as Delivery Mechanism
Rather than treating the scaffold as a passive container, KINETIX is developing structures where geometry itself is intended to play a functional role in delivery. How a scaffold is built may influence what it delivers and over what timeframe.
Computational Design Approach
KINETIX uses computation to guide the scaffold architecture development process, aiming to explore design options in a more systematic and directed way than manual iteration alone would allow.
Investigational technology,
currently in development.
KINETIX technology is at a research and preclinical development stage. It is not approved for clinical use in any jurisdiction and has not been evaluated in human clinical trials.
Scaffold Design
Developing and iterating scaffold architectures intended for localized post-resection delivery, with a focus on GBM applications.
Material Development
Investigating biomaterials and fabrication approaches suitable for the target application, with attention to biocompatibility and processability.
Preclinical Validation Planning
Designing evaluation approaches to characterize scaffold performance in relevant preclinical models. No clinical studies have been conducted.
Translational Partnerships
Engaging with academic, clinical, and research partners to inform development direction and build toward future translation pathways.
Interested in our development work?
We welcome conversations with researchers, clinicians, and potential partners.
An early-stage company building toward a new approach to localized delivery.
KINETIX is an early-stage biomedical company. We are developing the tools, methods, and scaffold systems that underpin our approach to localized therapeutic delivery. Our work is currently preclinical.
We are building deliberately, starting with a well-defined clinical problem (GBM post-resection delivery), using it to develop and validate our platform, and working toward eventual translational pathways in partnership with the broader research and clinical community.
Preclinical Development
Research and early-stage development. No clinical studies conducted.
Phoenix, AZ, USA
Based in the Phoenix metro area.
Scaffold Platform Development
Building a scaffold design and fabrication platform. GBM is the initial application.
contact@kinetix-dds.com
We welcome outreach from researchers, clinicians, and potential partners.
Start a conversation.
We welcome outreach from researchers, clinicians, strategic partners, and others interested in our development work.
Prefer a direct conversation?
Submit the form and indicate your interest. We will follow up within 1–2 business days to arrange a call with the right member of our team.